Legend Biotech Corporation recently declared a financial loss in the fourth quarter, although the loss margins were less than the estimated figures sought by financial analysts.
During this financial period, the company's overall earnings came up to -$144.818 million or -$0.40 per share, showing an improvement from last year's fourth quarter which stood at -$135.876 million, or -$0.41 per share.
Analysts' forecasts, collated by Thomson Reuters, had initially predicted the firm's earnings to be -$0.83 per share, excluding any special items.
On another positive note, Legend Biotech Corporation's revenue significantly increased by 187.6% in the fourth quarter, surging up to $79.464 million from $27.633 million recorded last year.
Here's a quick glance at Legend Biotech Corporation's earnings report (GAAP):
- Earnings (Q4): -$144.818 Million compared to -$135.876 Million last year.
- EPS (Q4): -$0.40 compared to -$0.41 last year.
- Revenue (Q4): $79.464 Million compared to $27.633 Million last year.
